Researchers are set to announce positive results from a trial of ReNeuron Group's stem cell treatment for the damage caused by stroke, CEO Michael Hunt said. The findings are expected to be presented this month at a conference in London. "It sets us up nicely for a Phase II efficacy trial," said Hunt.

Full Story:

Related Summaries